Fermenta Biotech Limited (Fermenta) proudly steps into its 75th year, beginning a momentous chapter in its journey of trust, ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Announce initial clinical data from Cohort 1 in the Phase 1/2 trial of PM359 for p47 phox CGD in 2025. The initial readout ...

President Donald Trump signed an executive order Monday updating guidance for researchers and government agencies with the ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) ...

Under the theme " Nurture the Present, Venture Forward ", the Food & Beverage lnnovation Forum 2025 (FBIF2025) and FBlF Food ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expect ...

Welcome to Definitive Healthcare's Q1 2025 earnings call. Later, we will conduct a question-and-answer session. I would now like to turn the call over to your host. You may begin. Good afternoon.

Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsMichaela Pewarski - Vice President, ...

Stocks in the Crossfire of the Tariff Uncertainty In investing, the phrase “this time is different” is dangerous. It leads people to ignore historical precedents and patterns. But the last time ...